Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00499694
Recruitment Status : Completed
First Posted : July 11, 2007
Results First Posted : August 25, 2014
Last Update Posted : June 12, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute

Brief Summary:

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as satraplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving satraplatin together with bevacizumab may kill more tumor cells.

PURPOSE: This clinical trial is studying how well giving satraplatin together with bevacizumab works in treating patients with metastatic prostate cancer previously treated with docetaxel.

Condition or disease Intervention/treatment Phase
Prostate Cancer Biological: bevacizumab Drug: satraplatin Not Applicable

Detailed Description:



  • Determine the time to progression in patients with metastatic androgen-independent prostate cancer previously treated with docetaxel currently treated with satraplatin and bevacizumab.


  • Determine the toxicity of this regimen in these patients.
  • Assess the prostate-specific antigen (PSA) response rate in patients treated with this regimen.
  • Determine the overall survival of patients treated with this regimen.
  • Assess changes in levels of N-terminal collagen peptide (NTX) and bone-specific alkaline phosphatase (BSAP) in patients treated with this regimen.
  • Correlate urine NTX and serum BSAP levels with time to progression in patients treated with this regimen.

OUTLINE: Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral satraplatin on days 1-5. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for 28-42 days.

PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Bevacizumab and Satraplatin in Docetaxel Treated Metastatic Androgen Independent Prostate Cancer
Study Start Date : October 2007
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Bevacizumab and Satraplatin

Bevacizumab 10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)

Satraplatin 80 mg/m(2), Orally, Days 1-5, every 35 days

Biological: bevacizumab
10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
Other Name: Avastin ®

Drug: satraplatin
80 mg/m(2), Orally, Days 1-5, every 35 days

Primary Outcome Measures :
  1. Time to Progression [ Time Frame: Every 70 days ]
    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. TTP is measured using Kaplan-Meier product-limit.

Secondary Outcome Measures :
  1. Toxicity, Presented as the Number of Participants With Adverse Events [ Time Frame: Day 1 of every cycle (35 days) and Day 15 of every cycle ]
    Toxicity was categorized according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3.0).

  2. Percentage of Participants With Prostate-specific Antigen (PSA) Response [ Time Frame: Day 1 of every cycle (35 days) and Day 15 of every cycle ]
    Prostate-specific antigen (PSA) response rate as measured by a 50% or better decrease in PSA levels

  3. Overall Survival [ Time Frame: Followed every 3 months after treatment is discontinued ]
    Overall survival using the Kaplan-Meier method

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the prostate, meeting the following criteria:

    • Metastatic disease
    • Objective progression or rising prostate-specific antigen (PSA) despite androgen-deprivation therapy and antiandrogen withdrawal
  • Patients with rising PSA must demonstrate a rising trend with 2 successive elevations at a minimum interval of 1 week

    • Minimum PSA of 5 ng/mL or new areas of bony metastases on bone scan required if no measurable disease
    • No minimum PSA for measurable disease
  • Must have received ≤ 1 prior docetaxel-based chemotherapy for metastatic disease
  • No known CNS disease or brain metastases
  • Testosterone < 0.5 ng/mL (castrate level)

    • Concurrent luteinizing-hormone releasing-hormone agonist allowed to maintain castrate level


  • Zubrod performance status 0-1
  • Life expectancy ≥ 12 weeks
  • Absolute neutrophil count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 8.0 g/dL
  • Bilirubin normal
  • Creatinine ≤ 2 mg/dL OR creatinine clearance ≥ 50 mL/min
  • Urine protein:creatinine ratio ≤ 1.0 OR proteinuria ≤ 2+ by urine dipstick OR ≤ 1 g protein/24-hour urine collection
  • Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment
  • No significant traumatic injury within the past 28 days
  • Adequately controlled hypertension (defined as systolic blood pressure [BP] ≤ 150 mm Hg and/or diastolic BP ≤ 100 mm Hg on antihypertensive medications)
  • No history of hypertensive crisis or hypertensive encephalopathy
  • No New York Heart Association class II-IV congestive heart failure
  • No myocardial infarction or unstable angina within the past 6 months
  • No stroke or transient ischemic attack within the past 6 months
  • No significant vascular disease (e.g., aortic aneurysm, aortic dissection)
  • No symptomatic peripheral vascular disease
  • No evidence of bleeding diathesis or coagulopathy
  • No prior malignancy except adequately treated skin cancer or any other cancer in complete remission for ≥ 2 years
  • Able to swallow and retain capsules
  • No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
  • No serious nonhealing wound, ulcer, or bone fracture
  • No known hypersensitivity to any component of bevacizumab
  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to bevacizumab
  • No uncontrolled intercurrent illness, including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
  • No psychiatric illness or social situation that would preclude compliance with study requirements
  • No HIV positivity
  • No immune deficiency


  • See Disease Characteristics
  • More than 4 weeks since prior flutamide
  • More than 6 weeks since prior bicalutamide or nilutamide
  • At least 4 weeks since prior radiotherapy
  • At least 2 weeks since prior minor surgery
  • More than 7 days since prior core biopsy or minor surgery (excluding placement of a vascular access device)
  • More than 28 days since prior major surgery or open biopsy (8 weeks if high-risk procedure such as liver resection, thoracotomy, or neurosurgery)
  • Concurrent low-dose aspirin (≤ 325 mg/day) allowed
  • Concurrent anticoagulants allowed if patient has been on therapy ≥ 4 weeks and has no acute thromboembolic activity
  • No concurrent major surgery
  • No concurrent aprepitant
  • No concurrent immunosuppressive therapy
  • No concurrent combination anti-retroviral therapy for HIV-positive patients
  • No other concurrent antitumor therapy (including radiotherapy)
  • No other concurrent investigational agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00499694

United States, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, United States, 48201
Sponsors and Collaborators
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Study Chair: Ulka N. Vaishampayan, MD Barbara Ann Karmanos Cancer Institute

Additional Information:
Responsible Party: Ulka Vaishampayan, Principal Investigator, Barbara Ann Karmanos Cancer Institute Identifier: NCT00499694     History of Changes
Other Study ID Numbers: CDR0000518085
P30CA022453 ( U.S. NIH Grant/Contract )
WSU-2006-118 ( Other Identifier: Barbara Ann Karmanos Cancer Institute )
First Posted: July 11, 2007    Key Record Dates
Results First Posted: August 25, 2014
Last Update Posted: June 12, 2018
Last Verified: May 2018

Keywords provided by Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute:
stage IV prostate cancer
recurrent prostate cancer
adenocarcinoma of the prostate

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action